Key facts
- Shunjing Pharmaceutical’s last known valuation is $746.3M.
- It has raised $41.5M.
- Notable investors include Green Pine Capital Partners, Hotgen.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Shunjing Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Shunjing Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shunjing Pharmaceutical
Operator of a biopharmaceutical firm intended to discover antibody drugs. The company has built an international layout of innovative antibody drugs for chronic diseases, involving the treatment of cardiovascular, cerebrovascular, tumour, neurodegenerative and other diseases.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Ownership
- Privately Held (backing)
Shunjing Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shunjing Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shunjing Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.